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Abstract
Background: Despite increased resources over the past few years the coverage of malaria control interventions is
still inadequate to reach national and international targets and achieve the full potential of the interventions to
improve population health. One of the reasons for this inadequate coverage of efficacious interventions is the
limited understanding of the optimum delivery systems of the interventions in different contexts. Although there
have been debates about how to deliver interventions, the methods for evaluating the effectiveness of different
delivery systems have rarely been discussed. Delivery of interventions is relatively complex and a thorough
evaluation would need to look holistically at multiple steps in the delivery process and at multiple factors
influencing the process. A better understanding of the strength of the evidence on delivery system effectiveness is
needed in order to optimise delivery of efficacious interventions.
Methods : A literature review was conducted of methods used to evaluate delivery systems for insecticide treated
nets, intermittent preventive treatment in pregnant women, and treatment for malaria in children.
Results: The methodology of delivery system evaluations varied. There were inconsistencies between objectives
and methods of the evaluations including inappropriate outcome measures and unnecessary controls. There were
few examples where the delivery processes were adequately described, or measured. We propose a cross sectional
observational study design with attribution of the outcomes to a specific delivery system as an appropriate
method for evaluating delivery systems at scale.
Conclusions: The proposed evaluation framework is adaptable to natural experiments at scale, and can be applied
using data from routine surveys such as the Demographic and Health Surveys, modified by the addition of one to
two questions for each intervention. This framework has the potential to enable wider application of rigorous
evaluations and thereby improve the evidence base on which decisions about delivery systems for malaria control
and other public health interventions are taken.
Introduction
The efficacy of insecticide treated nets (ITNs) [1,3,4],
intermittent preventive treatment in pregnant women
(IPTp) [5-9] and artemisinin combination therapies
(ACTs) [10-12] have been proven. However, coverage of
these interventions is still low: the most recently avail-
able data indicate that among populations at risk, only
24% of children under 5 years of age use a treated net,
20% of pregnant women receive at least two doses of
IPTp, and less than 15% of febrile children receive
prompt treatment with an ACT. [13]. Whether insecti-
cide treated nets should be delivered free of charge,
whether they should be delivered through the public or
private sector, and whether through routine systems or
campaigns is debated. The low coverage of IPTp deliv-
ered through routine antenatal care has prompted ques-
tions on whether delivery of IPTp through community
based systems could increase coverage. Interventions to
improve access to ACT through public, private and
community based delivery systems are being implemen-
ted. Despite these debates about how to scale-up the
delivery of these interventions, there has been little dis-
cussion of the methods of evaluation of the effectiveness
of different delivery systems, limiting understanding of
the strength of the evidence base on which the merits of
different systems can be considered.* Correspondence: Jayne.Webster@lshtm.ac.uk
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Delivery systems have two components: (1) the chan-
nels through which a product moves from the national
level to the end user; (2) the strategies applied to facili-
tate movement of the product from step to step of the
delivery channel. The delivery channels may be within
the public sector such as antenatal clinics (ANC) and
campaigns, the private sector such as Licensed Chemical
Sellers, or composed of a mix of the two such as vou-
cher schemes for ITNs. The strategies to facilitate move-
ment of the product applied to these channels include
pricing policies (level of subsidy), the type or brand of
product, the extent and form of training of health work-
ers, and the formulation and packaging of the drugs.
There are therefore a multitude of potential delivery sys-
tems for most public health interventions and most
interventions will be delivered at any one time through
more than one delivery system (different channels, stra-
tegies, or both). A public health programme such as a
malaria control programme will consist of multiple pro-
ducts delivered through a multitude of delivery systems.
Evaluation of the effectiveness of delivery systems is
essential to identify optimum delivery systems to scale
up interventions. However, the methodology for evaluat-
ing delivery systems has not been well defined. Evalua-
tions in general have focussed on the effectiveness of
the intervention, or on the health impact of public
health programmes. Approaches proposed for pro-
gramme evaluation provide a useful framework for
development of delivery system evaluations. Three types
of programme evaluation have been defined based upon
the strength of inference of the causal relationship
between the interventions that are implemented and the
outcomes. In increasing order of complexity and
strength of inference, these are adequacy, plausibility,
and probability evaluations [14]. The UK Medical
Research Council has developed a similar framework for
evaluating ‘complex interventions’ where they acknowl-
edge the need to examine the causal pathway of inter-
ventions, which they call a process evaluation [15].
Although primarily developed from experience within
high income countries, this approach may be adapted to
the needs of programme evaluation within the develop-
ing country context. Examples of this approach to date
have mainly been conducted within the context of Ran-
domised Controlled Trials (RCTs).
Although there have been calls for scaling up the
delivery of effective interventions over the last few years
[16,17] there have been few advances in how to assess
the effectiveness of the systems required to achieve this
objective. In order to optimise delivery of efficacious
interventions it is critical to understand the way in
which these delivery systems have been evaluated so as
to assess the strength of the evidence base. Our
objective is therefore to review the methods used in
evaluations of delivery systems for ITNs, IPTp, and
effective case management for febrile children; and,
drawing on the findings from this review and upon ele-
ments of programme evaluation methodology, to
develop a relatively simple approach to delivery system
evaluation applicable to use by a wide range of
programmes.
Methods
We reviewed evaluations of the delivery of ITNs, IPTp,
and case management of malaria in febrile children that
were found in the PubMed electronic online database
(US National Library of Medicine, Bethseda, USA). Key
search terms used were insecticide treated nets, ITNs,
bednet, bed net, intermittent preventive treatment, IPT,
IPTp, malaria treatment, malaria case management,
delivery, distribution, coverage, adherence, and evalua-
tion. The titles and abstracts were checked for relevance
to the evaluation review. The reference list of each iden-
tified paper was searched for further relevant
publications.
Studies were included if they involved evaluation of
the delivery of ITN, IPTp or ACT through one specific
delivery system, through multiple systems, or through a
new delivery system. Because IPTp is almost exclusively
delivered through ANC, studies of coverage of IPTp
were included; in contrast, ITNs and effective case man-
agement for malaria may be delivered through a myriad
of systems and therefore studies of coverage of ITNs
and effective case management for malaria were
excluded unless they referred to a specific delivery sys-
tem(s), or a component of a specific delivery system.
This review focused on the delivery channel. Thus, eva-
luations of delivery strategies to improve uptake and use
such as pricing policies, pre-packaging of drugs, educa-
tion of providers and other such strategies were
excluded. For each study, the defined objective, evalua-
tion method, primary outcome, type of control and scale
were extracted.
Objectives and approaches to evaluation from the
public health programme literature and the complex
evaluation literature were used to develop a framework
for delivery system evaluation and to discuss the limita-
tions of the reported delivery system evaluations.
Results
Review of delivery system evaluations
An initial screening of 1,039 study titles identified 65
papers on ITNs, 16 on IPTp, and 54 on effective case
management of malaria, that were relevant to delivery
system evaluation. Upon reviewing the abstracts of these
publications, 27 of the ITN, 6 of the IPTp, and 17 of
the effective case management papers met the inclusion
criteria. The majority of the ITN paper exclusions were
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due to a lack of focus on a delivery system. Excluded
IPTp papers included those where health outcomes
rather than coverage outcomes were reported, where the
focus was on effect modifiers, for example the influence
of timing of ANC visits on IPTp coverage [18], and
where there was no empirical data. The reasons for
exclusion of papers focused on case management were
relatively wide ranging including: health rather than cov-
erage outcomes, a specific focus on diagnosis, qualitative
studies, descriptive analyses of routine data, focus on
training of health workers and other effect modifying
strategies.
Studies remaining in the review were divided into eva-
luations of new delivery systems and evaluations of
existing delivery systems (including components of sys-
tems). Studies of ITN delivery included 20 evaluations
of new systems, and 7 evaluations of existing systems
(Additional file 1). The IPTp studies included 3 evalua-
tions of new systems and 3 evaluations of coverage
achieved through existing (ANC) systems. For effective
case management 4 evaluations of new delivery systems
and 13 evaluations of one or more components of exist-
ing delivery systems were identified.
Insecticide Treated Nets
New systems for delivery of ITNs in the public sector
included routine delivery through ANC/EPI, campaign
delivery integrated with other interventions (immunisa-
tions and ivermectin), and voucher systems. In the pri-
vate sector, delivery has involved social marketing. Three
of the studies of new systems were comparisons of two
different systems, employer versus community based sys-
tems [19], sales through commercial shopkeepers versus
groups of community leaders [20], and social marketing
alone and together with free delivery through ANC [21].
Each of these 3 studies had a primary outcome of ‘the
proportion of households with at least one net/ITN’, one
was a cluster randomised controlled trial and the others
used observational cross sectional surveys with compari-
son between geographic areas where each of the inter-
ventions were implemented.
Amongst the 20 studies of new delivery systems 16
used observational cross sectional surveys, 5 including
both pre-and post delivery surveys through the new sys-
tem and 11 post- only. Two of the pre- and post deliv-
ery studies used an internal control, attribution of nets
in households to the system through which they were
delivered [22,23]; whilst the others used external geo-
graphic controls [24], and no controls [25]. Of the post-
delivery only surveys, 1 used the colour of the net to
attribute it to a specific delivery system, 5 used an his-
torical internal control, 3 used an external geographic
control, and 1 used no control. Historical internal con-
trols used questions in post ITN-vaccination campaigns
on ownership and/or use of ITNs pre campaign.
One out of the 7 studies with a focus on existing ITN
delivery systems aimed to evaluate two specific systems
[26], two evaluated one specific system [27,28], and the
remainder the mix of existing systems. Six of the studies
used observational cross sectional surveys and 6 col-
lected data in such way that it was possible to attribute
nets in households to the system through which they
were delivered.
Intermittent Preventive Treatment in Pregnancy
All 3 studies identified that evaluated new delivery sys-
tems for IPTp involved community based approaches,
one integrated with ivermectin delivery [29], and 2
stand alone [30,31] (Additional file 1). All three were
non-randomised intervention studies and involved exter-
nal geographic controls. The three studies that evaluated
delivery of IPTp through ANC were observational cross
sectional studies that did not include a control. Primary
outcome measures were the proportion of pregnant
women who received 1, 2 or >2 doses of IPTp.
Case management
Four studies were identified that evaluated new delivery
systems for case management of malaria. These included
home management/community based delivery mechan-
isms [32-34] and distribution by school teachers [34].
The primary outcomes were diverse, encompassing
receiving an ACT, receiving treatment according to pro-
tocol, and treatment incidence density per person-year.
A similar diversity was seen in the methods and controls
used in these 4 studies. One of the studies used an RCT
and the other 3 used observational cross sectional sur-
veys post-delivery only. Amongst the cross sectional sur-
vey evaluations 2 used external geographic controls and
one did not use a control. The 13 evaluations of existing
delivery systems for malaria case management were
diverse in their objectives, and primary outcomes ranged
from evaluations of quality of case management after a
policy change to studies on adherence. However, the
majority of the studies used observational cross sectional
surveys either at health facilities or the household, and
did not use controls.
A framework for delivery system evaluation
Our review found that evaluations of delivery systems
for malaria control interventions have been diverse in
their objectives, outcomes measured, methods and con-
trols used. The type of control used is a major factor in
determining the strength of inference that the outcomes
were due to the delivery system. However, different
types of controls introduce different levels of complexity
and resource needs (research costs).
We identified only 3 published evaluations of delivery
systems for malaria control interventions that had taken
place at the national level [22,35,36]. An effective deliv-
ery system (or mix of delivery systems) should be able
Webster et al. BMC Health Services Research 2010, 10(Suppl 1):S8
http://www.biomedcentral.com/1472-6963/10/S1/S8
Page 3 of 11
to deliver the intervention to the entire target group, on
a large scale. There should be no disparities in the cov-
erage of the intervention between sub groups of the tar-
get population, for example to different socio-economic
groups. The effectiveness of the delivery system in
reaching different population groups is likely to vary, as
is its relative effectiveness at the small and large scale.
We explore the evaluation elements required and pro-
pose a framework for the evaluation of delivery systems
for malaria control interventions.
Objectives and outcome measures of delivery system
evaluations
The first step in designing a delivery system evaluation
is to define the purpose and objectives of the evalua-
tion (Table 1). Generally the effectiveness of a delivery
system in reaching the maximum target population is
assessed. Thus the primary outcome measure in a
delivery system evaluation is coverage of the interven-
tion achieved through the specific delivery system(s)
(Figure 1). Secondary outcomes include tempo (how
quickly a system can reach high coverage), equity (the
socio-economic distribution of coverage achieved), cost
and/or cost-effectiveness, and others. Primary outcome
measures are classified further into proximal and distal
outcomes (Table 2). Proximal outcomes are those
intrinsically linked to delivery such as ownership of an
ITN, delivery of a dose of IPTp, and delivery of an
ACT and therefore measure the effectiveness of the
causal chain or the intermediate steps within the
delivery system. Distal outcomes relate to use of the
intervention once it has been delivered, such as use of
an ITN by the target group, and adherence to an ACT
regimen, all of which may be mediated by factors
other than the delivery channel (e.g. the delivery stra-
tegies but also other factors). If IPT is delivered by
directly observed therapy (DOT) within the ANC then
this is a proximal outcome. However, if IPTp is pre-
scribed rather than given by DOT (or given to be
taken later) then use of the IPTp is a distal outcome
(Table 1). Thus the distal outcomes evaluate the steps
in the causal chain that are not entirely within the
delivery system. Measuring health outcomes (impact)
is not essential unless there is a plausible reason that
identical coverage of the intervention achieved via dif-
ferent delivery systems would result in different health
impacts.
The second step in conducting a delivery system eva-
luation is to clearly characterise the pathway of the
delivery system and to define the proximal and distal
coverage outcomes. For example, IPTp may be intended
to be delivered as DOT, however, if there is no water in
the health facility the woman may be given the SP to
take at home; similarly, stock outs of SP may result in
the woman being given a prescription for the SP. The
absence of SP in the ANC and the absence of water in
the ANC are independent ‘implementation related fac-
tors’ [37]. The probability of a pregnant woman receiv-
ing 2 doses of SP-IPT will therefore be the product of
these events in the pathway of the IPT delivery system.
Table 1 Steps in designing a delivery system evaluation
Examples Comments
Determine the
purpose of the
evaluation
- To evaluate a new delivery system for ITNs
- To evaluate a new delivery system for IPTc
- To assess the delivery of IPTp through ANC
Evaluation of a new delivery system for an existing intervention requires a
pre-post survey with attribution of nets by source. A process analysis is
required to assess the outputs at each intermediate step in the causal
chain of delivery
Select the
evaluation method
- cross sectional pre-post survey with attribution
of outcomes by source of intervention
- cross sectional post intervention survey with
attribution of outcomes by source of
intervention
- cross sectional post only survey with no
control
For evaluation of a new delivery system for an existing intervention a
pre-post survey with attribution of outcomes by source would provide
causality for proximal indicators and plausibility inference for distal
indicators.
Define the outcome
indicators
- the proportion of children under 5years using
an ITN
- the proportion of children under 5 years taking
a full course of IPT
- the proportion of pregnant women who
attend ANC receiving at least 2 doses of IPT
The primary outcome indicator may be a distal or proximal indicator
Define the pathway
of delivery
- include several proximal and more than one
distal steps
- includes several proximal and one distal steps
- the evaluation terminates at proximal steps
The number of steps varies with interventions and with delivery systems.
Many pathways are linearNot all pathways are linear
Characterise the
contextual factors
- malaria transmission levels
- structure of the health system
- socio-demographics of the population
Disaggregate outcomes by contextual factorsDescribe contextual factors
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It is plausible that the relationship between the proxi-
mal coverage outcome and the distal coverage outcome
would depend upon the system through which the inter-
vention is delivered. For example, pregnant women and
children under 5 years receiving free ITNs delivered
through ANC may be more, or less, likely to use the
ITNs than those mothers and children obtaining ITNs
delivered through social marketing in the retail sector,
or from the informal private sector. Children may be
more or less likely to be given a full dose of ACT (cor-
rect number of tablets each time, correct number of
times per day, correct number of days) if their carers
get the drug from the public sector than from the pri-
vate retail sector.
The relationship between distal outcomes and health
impact is dependent upon the intervention itself and
upon the context. Similar distal coverage outcomes of
an intervention could result in different health impacts
among different population groups including different
age groups, those living in different transmission inten-
sity areas, and different socio-economic groups. How-
ever, it is unlikely that this difference in health impact is
Figure 1
Table 2 examples of proximal and distal coverage outcomes for three malaria control interventions
Intervention Delivery
details
1st level of proximal
coverage outcome
Subsequent proximal coverage
outcomes
Distal coverage outcome
ITNs Direct delivery
through ANC
Proportion of households
owning at least one ITN
delivered through ANC
Proportion of the target group who slept
under an ITN delivered through ANC
IPTp Directly
Observed
Treatment
(DOT)
Proportion of pregnant
women taking 2 doses of
IPTp
None
Dose given
but not DOT
Proportion of pregnant
women given 2 doses of
IPTp
Proportion of pregnant women who take
2 doses of IPTp
SP prescription
given
Proportion of pregnant
women given 2 IPTp
prescriptions
Proportion of women who collect the SP Proportion of pregnant women who take
2 doses of IPTp
ACTs Delivery to
febrile children
through health
facilities
Proportion of febrile children
accessing public sector
health facilities for whom
ACT is prescribed
1. Proportion of carers of children
prescribed ACTs who collect the ACT
(correct number of tablets)2. Proportion of
carers of children who are explained the
dosing regimen
Proportion of children given ACTs who
take the correct dosing regimen (number
of tablets each time, number of times
each day, number of days)
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due to the system through which the intervention was
delivered. For example, if the population of one district
all use an ITN (distal coverage outcome) on the same
nights for the same number of hours during a one year
period the health impact may differ between children 0
to 2 years of age, children 3-5 years of age, older chil-
dren, and adults, but this difference in health impact
would not be related to the system through which the
ITN was delivered. In terms of the causal chain of the
intervention, the relationship between health impacts at
a given level of use is not directly linked to the delivery
system, whose impact is exerted upon proximal
outcomes.
In summary, delivery system evaluations should 1)
determine the purpose of the evaluation, 2) select the
evaluation method, 3) define the outcome indicators
(proximal, distal or both) 4) define the pathway of deliv-
ery, and 5) characterise the contextual factors. Each of
these steps in the evaluations may be undertaken for
unique delivery systems (where only one system is oper-
ating) and for specific multiple delivery systems within a
mixed system.
Attribution of coverage outcomes to a specific delivery
system as an internal control
If an intervention is delivered through a unique system,
then coverage outcomes can be directly attributed to
this specific delivery system. For example, Intermittent
Preventive Treatment for Infants (IPTi) is only delivered
through the Expanded Programme on Immunisation
(EPI). Where an intervention is delivered through more
than one system, then further methods are needed to
attribute the coverage achieved by each system. This has
been done for mosquito nets based on whether the net
was treated or not [38], upon the source or delivery
point of the net [39] and whether a voucher was used in
the purchase of the net [22,23]. A single cross sectional
survey may be used to assess the relative proportion of
coverage of an intervention that is due to one specific
delivery system, or to all known delivery systems. A new
delivery system introduced within existing multiple sys-
tems, can be evaluated by attributing the proportion of
coverage to each delivery system pre and post imple-
mentation of the new delivery system.
Attribution to specific delivery systems requires a sim-
ple way of matching the coverage to the system through
which it was achieved. All malaria control interventions
have a point at which they are delivered to the users.
The coverage of an intervention can be matched to a
specific delivery system by identifying the delivery point
at which the recipient received the intervention. This
can be done by adding a few questions to cross sectional
surveys. For example “where did you get this net” or
“where did you get these medicines for your child”?
This method assumes that the alternative delivery sys-
tems in operation for an intervention do not share the
delivery point of the system that is being evaluated.
However, if there are instances where two delivery sys-
tems share a delivery point (for example a voucher sys-
tem for ITNs, and subsidised delivery of ITNs through
ANC clinics) then further questions will be needed to
distinguish the two.
Assessing proximal coverage outcomes
Evaluations should consider the simplest way of achiev-
ing their objectives whilst maintaining internal validity
of the methods used, and the external validity of the
findings.
Internal validity
An internally valid evaluation minimises random and
systematic errors due to chance, bias, and confounding
[40]. Data collection methods for delivery system evalua-
tion should be internally valid and should apply statisti-
cal methods in the analysis to assess random errors and
adjust for any potential confounding effects. Well
designed RCTs have strong internal validity as they
minimise both random and systematic errors. However,
assessment of a number of delivery systems using an
RCT would be prohibitively complex and expensive, and
potentially infeasible. Cross sectional observational stu-
dies are generally of weaker internal validity than are
RCTs. However, using structured random sampling
techniques to select an adequate number of appropriate
units can reduce selection bias and random errors, and
data on potential, confounding factors can be collected
and accounted for in the analysis.
Inference
Where an intervention is delivered through a single sys-
tem, then the proximal coverage outcomes can be
directly attributed to this delivery system and it is
appropriate to infer that the delivery system had a cau-
sal relationship to the proximal coverage outcome.
However, unless the intervention is new, then it cannot
be assumed that it is delivered through only one system.
In this situation either formative work must be underta-
ken to ensure that there is only one delivery system in
operation, or a question on source should be included
in the evaluation. Where a new delivery system is evalu-
ated within the context of multiple existing delivery sys-
tems, if the relative proportion of the proximal coverage
outcome is attributed to each of the delivery systems,
then a plausibility statement can be made on what pro-
portion of the outcome was due to the new delivery sys-
tem. In this type of evaluation, the existing delivery
systems are acting as internal controls and thus it is
possible to infer that the changes in coverage were due
to the new delivery system, above and beyond the influ-
ence of other external factors. As proximal outcomes,
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such as coverage of IPTp in any delivery system using
DOT, are direct outcomes of the delivery systems, the
contextual factors that play a role in this outcome are
integral to all delivery systems that are assessed. These
contextual factors should be described and their effect on
the coverage outcome should be assessed where possible.
External validity
The findings of a controlled trial may have limited
external validity even with respect to the population in
the area in which the trial was conducted. Well con-
ducted cross sectional observational studies will have
good generalisability to the population from which they
were sampled. Therefore if a survey is undertaken at the
national level, then the findings are generalisable at the
national level. Characterisation of the contextual factors
that are present in the area of implementation will help
to inform a judgement as to the other geographic areas
to which the findings may be generalised.
Assessing distal coverage outcomes
Distal coverage outcomes measure the use of an inter-
vention by the target population, and they are the pri-
mary link between intervention coverage and health
impact.
Internal validity
Distal coverage outcomes are measured in the same way
as proximal coverage outcomes through RCTs or cross
sectional observational studies. The methodological
issues in the internal validity of proximal coverage out-
comes mentioned above would therefore apply to that
of distal coverage outcomes.
Inference
The effect of the “user related factors” that influence the
distal coverage outcomes may vary depending on the
way the intervention was delivered (implementation
related factors), or there may be external factors that
modify the distal coverage outcomes. The effect of
implementation related factors on the distal coverage
outcome may be assessed by measuring the relative
dose-response relationship (although care must be taken
to assess any selection biases in the dose received)
[14,40]. For example the relationship between ownership
and use of ITNs from specific delivery systems can be
measured. External factors are more difficult to define
and to assess. For example, the proportion of those
owning an ITN who use it may depend upon factors
such as season (temperature), levels of biting nuisance,
housing characteristics, irrespective of the system
through which they got the ITN. If use of ITNs amongst
those owning them is attributed to specific delivery sys-
tems then the other delivery systems act as an internal
control for external factors. This would enable a plausi-
bility inference as to the observed association between
ITN use and a specific delivery system.
External validity
There are factors additional to those confounding proxi-
mal coverage outcomes that may confound the relation-
ship between the delivery system and the distal coverage
outcomes. As in the case of proximal coverage out-
comes, the findings of a controlled trial for distal cover-
age outcomes may have very limited external validity.
Again the external validity of cross sectional observa-
tional studies depends upon a population level represen-
tative sampling scheme and upon characterisation of the
implementation context.
Assessing steps in the causal pathway of delivery
In an effective delivery system, the intervention will pro-
gress through each intermediate step with minimal loss,
for example, all febrile children prescribed an ACT will
receive the correct number of tablets. It is likely in prac-
tice however, that there will be some loss at each stage
of the delivery process. For example, some febrile chil-
dren prescribed an ACT will be given artesunate mono-
therapy, or insufficient tablets to complete effective
treatment. In order to assess the steps on the causal
pathway of delivery of an intervention it is necessary to
define these steps. The evaluation can then be designed
to assess the proportion of the population that progress
successfully through each step. Often during implemen-
tation, variations to the causal pathway will be intro-
duced. These may involve health worker strategies for
coping with drug stock-outs such as writing a prescrip-
tion and sending the child to another health facility or
the private market. Where important blockages in the
steps of the causal pathway are identified, for example
those eligible for an intervention not being offered it
[23], then further research is needed to identify the rea-
sons why the problems occur. Once the problems have
been identified steps may be taken to prevent them
reoccurring. Factors that impact upon the delivery sys-
tem are termed implementation related factors, and they
function as effect modifiers.
Assessing the factors that influence the relationship
between proximal and distal coverage outcomes
Factors influencing the relationship between proximal
and distal outcomes can be related to 1) delivery system,
2) the intervention, 3) the target group, and 4) context
and factors external to the delivery system. For example
the delivery point of an ITN, and the accompanying
information and education, is likely to influence house-
hold ownership, but may also affect use of ITNs that are
already owned.
For example, the delivery point for an ITN is more
likely to influence household ownership than use of
ITNs. It is possible however, that the strategies that
make up the delivery system may influence use, for
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example, whether the ITN was given free of charge or
was purchased. Information exchanged during delivery
may also affect use or patterns of intra-household use.
The nature of the ITN, such as its shape, material or
colour may influence whether it is used. Target group
characteristics include number of household members,
number of ITNs owned, education of the household
head and their spouse, and socio-economic status.
External factors include season, levels of biting nuisance,
cultural norms etc. The external factors will have an
equal influence on households with ITNs delivered
through different systems and therefore do not necessa-
rily need to be measured, but should be described.
Other factors influencing selection of method
Policy status
Depending upon the policy status of the intervention to
be delivered, it may not be possible to include control
groups to whom the intervention will not be delivered.
Where an intervention is part of the national policy it is
unethical and likely to be politically impossible to sys-
tematically exclude sub groups of the population from a
particular delivery system. In this situation, delivery sys-
tem evaluations would therefore need to compare out-
comes among those receiving the intervention through
one delivery system compared to an alternative system,
or through a combination of the two.
Cross sectional observational studies are not limited
by whether an intervention is policy or not. As they are
able to use internal controls, cross sectional observa-
tional studies are applicable to evaluating the role of
alternative delivery systems in operational contexts, and
to evaluating proximal and distal outcomes of interven-
tions. For example, evaluation of the delivery of ITNs
through ANC in an area with ongoing delivery of ITNs
through social marketing would assess the relative pro-
portion of the coverage due to delivery through ANC
compared with that achieved through social marketing,
and other systems in operation such as the formal and
informal private sectors.
Scale
RCTs are not usually conducted at scale because they
are very expensive, prohibitively difficult, and randomi-
sation to intervention and control groups on a large
scale is practically and politically difficult. The complex-
ity and level of feasibility of evaluating at scale depends
upon the type of RCT. The most feasible would be to
randomise relatively large geographic areas , such as dis-
tricts or sub-districts, and allocate these to different
delivery systems [40].
Where a delivery system is in operation at the national
level, pre and post implementation cross sectional
observational studies can be undertaken using standard
sampling techniques to provide coverage estimates
attributable to the delivery system being evaluated that
are representative at the national level.
Discussion
In evaluating the effectiveness of a delivery system we
wish to know the proportion of the target population
that have been reached with the intervention, and
whether there are any geographic or socio-economic
disparities in coverage. Where coverage is less than
required, we also need to know where on the causal
pathway of intervention delivery the problems are
located. In order to provide the link between delivery
system effectiveness and the health outcomes we should
also assess the use or adherence to the intervention by
the target population. Assessment of health outcomes is
not necessarily required for delivery system evaluations.
If a need to measure health outcomes is identified, then
an evaluation of the intervention itself is required,
which may or may not, include delivery system effective-
ness as a composite element of the evaluation.
Different approaches to evaluation of delivery systems
for ITNs as compared with IPTp and effective case
management are likely to have been influenced by the
nature of the intervention. Mosquito nets to which
insecticide treatment is added to produce an ITN have
been household goods in most of Africa, but particularly
in West Africa, for many years. They have therefore
been delivered through a variety of systems, and there is
no innately obvious appropriate system through which
they should be delivered to reach the whole target popu-
lation. Consequently, delivery system evaluations have
covered a range of options, and evaluation methods
have generally been aimed at assessing the relative cov-
erage attributable to existing delivery systems, or to new
ones within the context of those existing, and to the
population groups targeted. IPTp and effective case
management, however, are drug based, and national pol-
icy usually dictates that they should be delivered
through public sector health facilities, and often in com-
bination with other delivery systems, for example poli-
cies in many countries now allow delivery of ACTs
through the private sector. With a target group of preg-
nant women, ANC is the obvious delivery system for
IPTp. Alternative delivery systems would be required if
the target population were not being reached through
ANC.
There is unlikely to be a situation where ITNs are
delivered by one system alone. As such, there will
always be the need to attribute outcomes to specific
delivery systems and the possibility of using the other
delivery systems as internal controls. This should negate
the need for external (geographic) controls and rando-
mization. For example, in the cluster randomized trial of
introduction of a new delivery system for ITNs within
Webster et al. BMC Health Services Research 2010, 10(Suppl 1):S8
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the context of an existing delivery system by Mueller
et al [21], the use of a randomized control introduced
unnecessary complexity. Rather than using a cross sec-
tional survey pre and post RCT to assess the proximal
coverage outcome, cross-sectional surveys pre and post
implementation in routine operational conditions with
attribution of the proximal coverage outcome to the
specific ITN delivery systems would have been sufficient
to achieve the objective of this evaluation. This
approach would provide useful information about the
effectiveness of each of these systems, and whether they
are complementary or competing.
Other ITN delivery system evaluations have used
longitudinal cohort studies and observational cross sec-
tional surveys with attribution of the outcomes to the
system through which they reached the target popula-
tion. The outcomes of these studies have been both
proximal and distal coverage outcomes. Although it has
not always been noted within the reports, these studies
have demonstrated either causality for the proximal out-
comes or at the least strong plausibility that the distal
outcomes were due to the delivery systems being
studied.
Few studies have described in sufficient detail the
structure of the delivery systems being evaluated, and
only in a minority has the causal pathway been
described [20,41] and several proximal outcomes
assessed [22,23,42,43]. Generally, very little information
is provided on the causal pathway of the delivery of the
intervention. Only by describing the causal pathway is it
possible to identify the implementation effect modifiers
and to ensure that these are included in evaluation.
There is perhaps a greater tendency towards assessment
of health outcomes (that is evaluation of the effective-
ness of the intervention) than to greater exploration of
the delivery system and its enabling and disabling
factors.
Evaluations of the delivery of IPTp have mostly
involved the use of non-randomized controls. These stu-
dies have involved delivery of IPTp through 2 or more
systems. As for the delivery of ITNs, where doses of
IPTp are attributed to specific delivery systems, external
controls are unnecessary. Non-randomized external geo-
graphic controls may be subject to a myriad of confoun-
ders which influence the relationship between the
delivery system and the outcomes. Where a new delivery
system is implemented it is essential that evaluations
provide information on the period of time between
implementation and evaluation as the tempo of different
delivery systems in achieving increased coverage with
interventions will differ.
There have been few evaluations of new systems for
delivering effective case management to febrile children
and there has been no common methodological
approach. Study designs are complicated by the choice
of whether to include [inclusion or exclusion of] diagno-
sis for the presence of malaria parasites.
In summary, where an intervention is delivered
through two or more systems, attribution of outcomes
to the specific delivery systems will enable a causal
inference that proximal outcomes were due to the sys-
tem through which they were delivered, and a plausible
inference for distal outcomes. Each delivery system
functions as an internal control for the other systems
and as such is affected by existing external contextual
factors. Implementation effect modifiers are internal to
each specific delivery system. The causal pathway of the
delivery system should be defined so that proximal out-
come indicators at each step can be determined and
assessed. Likely effect modifiers at each of these steps
may then also be identified and included within the eva-
luation. If health outcomes need to be measured then
an intervention effectiveness study should be conducted
rather than a delivery system evaluation. This methodol-
ogy may be applied to the conventional cross sectional
surveys addressed here, or could also be applied to mod-
els of continuous surveys as recently recommended by
Rowe et al [44].
Conclusions
The practical implications of this evaluation framework
are that observational cross sectional surveys can be
implemented on a large scale, and applied easily to
either the evaluation of new delivery systems, natural
experiments, or to evaluation of the current situation.
The addition of one to two questions per intervention
to national surveys such as the demographic and health
surveys would enable such evaluations at little or no
extra cost.
Additional material
Additional file 1: Summary of delivery system evaluationsSummary
of delivery system evaluations
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